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Abstract
High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive 
system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin + etoposide) is considered 
the first-line palliative treatment. Etoposide is frequently administered intravenously; however, oral etoposide may be used 
as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- and intra-patient variability and 
patient compliance. We aimed to evaluate possible differences in progression-free survival (PFS) and overall survival (OS) 
in patients treated with oral etoposide compared to etoposide given as infusion. Patients (n = 236) from the Nordic NEC 
study were divided into three groups receiving etoposide as a long infusion (24 h, n = 170), short infusion (≤ 5 h, n = 33) 
or oral etoposide (n = 33) according to hospital tradition. PFS and OS were analyzed with Kaplan–Meier (log-rank), cox 
proportional hazard ratios and confidence intervals. No statistical differences were observed in PFS or OS when comparing 
patients receiving long infusion (median PFS 3.8 months, median OS 14.5 months), short infusion (PFS 5.6 months, OS 
11.0 months) or oral etoposide (PFS 5.4 months, OS 11.3 months). We observed equal efficacy for the three administra-
tion routes suggesting oral etoposide may be safe and efficient in treating high-grade GEP-NEN, G3 patients scheduled for 
cisplatin/carboplatin + etoposide therapy.
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Introduction
Gastroenteropancreatic neuroendocrine neoplasms (GEP-
NENs) with proliferation index (Ki67) > 20% and/or 
mitoses > 20 per 2 mm2 are aggressive tumors that belong 
to the Grade 3 (G3) group in the WHO classification of 
tumors of the digestive system with an expected 5-year 
survival of 16% [1–3]. The majority of these tumors are 
characterized as poorly differentiated and called neuroen-
docrine carcinomas (NECs) although a subgroup of well-
differentiated G3 tumors has been recognized recently [4]. 
In the most recent WHO classification, pancreatic well-dif-
ferentiated NENs G3 are denoted pancreatic NET-G3 [5].
GEP-NENs G3, excluding pulmonary NENs, account 
for approximately 50% of all NENs G3 with primary 
tumors in esophagus, stomach, pancreas, colon and rectum. 
However, they present with cancer of unknown primary 
(CUP) in 30% of the cases [6]. An increase in incidence 
has been observed during the last years. However, treat-
ment efficacy does not seem to improve at the same rate 
[3, 7]. In the Nordic NEC study of 305 patients, median 
overall survival (OS) was 11 months for patients treated 
with chemotherapy and 1 month for untreated patients. 
Pancreatic tumors showed a median OS of 15 months, 
while rectal and colon tumors had median OS of 10.0 and 
8 months, respectively, indicating that OS differs with pri-
mary tumor location [6, 8]. Other reported factors indicat-
ing a better prognosis are Ki67 index < 55%, normal serum 
lactate dehydrogenase (LDH) and platelet count as well as 
good performance status [6].
Platinum-based combination chemotherapy with cis-
platin/carboplatin and etoposide is the first-line treat-
ment for GEP-NENs [9, 10]. This treatment regimen has 
been agreed upon and is used by the Nordic, European 
and North American Societies of neuroendocrine tumors 
[11–13]. Clinical practices on route of administration 
of etoposide for these GEP-NEN patients differ and are 
mainly due to hospital specific recommendations.
Chemotherapy has for years been given through an 
intravenous (IV) route of administration for a variety of 
cancers although there has been a rise in oral anticancer 
drugs [14]. There is a general perception that anticancer 
drugs are best given intravenously but this has been chal-
lenged by the development of new formulations of drugs 
with increased stability and bioavailability. The grow-
ing number of alternatives in oral formulations is giving 
rise to a shift in attitudes and practices but still concerns 
remain [14, 15].
IV administration of etoposide holds several advan-
tages. The ability of etoposide to exert its topoisomer-
ase inhibitory effect is directly correlated to the concen-
tration and duration of etoposide in the blood [16]. IV 
formulations allow for a higher bioavailability of a drug 
in the blood stream and therefore have been seen as the 
preferred route of administration but this also comes with 
disadvantages such as long hospital stays and elevated 
costs for hospitals as well as impact on patients’ quality 
of life. Another disadvantage with IV administration is the 
use of solvents that are toxic upon repeated administration 
[15–17].
Oral etoposide is an alternative still being debated. Con-
cerns of using oral etoposide include the decreased bioavail-
ability, inter- and intra-patient variability as well as for the 
risk of decreased patient compliance [14, 17]. Most studies 
show a bioavailability of etoposide ranging between 30 and 
76% with a nonlinear absorption that decreases in bioavail-
ability with increased dosage.
In this study, we examined the differences in treatment 
efficacy measured as progression-free survival (PFS) and 
OS for patients receiving etoposide as short or long infusions 
(≤ 5 or 24 h) compared to oral etoposide (O.E.).
Materials and methods
Patient and tumor characteristics
This study cohort included patients diagnosed with a 
GEP-NEN G3 with a primary tumor located in esophagus, 
stomach, pancreas, colon, rectum and a subgroup of CUPs 
(Table 1). CUP was defined as a NEN G3 diagnosed in a 
patient with predominant abdominal metastases but where 
no primary tumor could be identified.
Patients were collected from the Nordic NEC study, 
resulting in 236 patients, diagnosed 1995–2012, in whom 
the route of etoposide administration could be verified. Clin-
ical data were obtained from the Nordic NEC register [6]. 
The cohort included patients that received platinum-based 
combination chemotherapy (cisplatin/carboplatin + etopo-
side); cisplatin was given as an infusion to all 236 patients. 
Patients were given etoposide as short infusion (≤ 5 h), long 
infusion (24 h), or oral tablet (O.E.). The choice of route of 
etoposide administration was based on hospital preferences, 
and thus, all patients at a certain hospital were treated in the 
same way.
All tumors were immunoreactive (IR) for synaptophy-
sin and/or chromogranin A (CgA) and all tumors had Ki67 
index ≥ 20% counted in hot spot areas.
Statistical analyses
Efficacy of etoposide in the three groups was assessed with 
regard to PFS and OS. The defined event was death from 
tumor progression. PFS was defined as the time from the 
first treatment until time of the first progression and OS was 
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defined as the time from diagnosis of NEN G3 until date of 
death from neuroendocrine cancer; or if event was not found, 
censored at date of last observation.
Kaplan–Meier plots were used for PFS and OS analysis, 
and the log-rank test was used to compare curve separation 
according to type of etoposide administration. Cox propor-
tional regression was performed for the estimation of hazard 
ratios (HRs) and confidence intervals (CIs). The two groups 
receiving IV infusions were compared to patients receiv-
ing O.E. Using a multivariate regression model, variables 
hypothesized to correlate with the clinical outcome were 
included to ensure that they would not confound with the 
analysis. These analyses were performed on dichotomized 
variables: sex (male vs. female), CgA (positive vs. negative), 
performance status ECOG (0 + 1 vs. 2 + 3), LDH (normal vs. 
elevated) and Ki67 (< 55 vs. ≥ 55%). All statistical analyses 
were performed using IBM SPSS statistics software (v25, 
USA).
Ethics
The study was approved and the need for consent was 
waived by the local ethics committee, Regionala etikprövn-
ingsnämnden (EPN), in Uppsala, Sweden (ref: 2008/397).
Results
Baseline patient characteristics
Of the 236 patients included, 170 (72%) were given long 
infusions, oral etoposide and short infusions were given to 
33 patients, respectively (Table 1). The median age in the 
whole cohort group was 61 years (range 27–85 years). Ki67 
index was > 55% in 54% of all the patients. All included 
patients died due to their malignant disease. The distribution 
of variables such as sex, performance status, CgA immu-
nohistochemical expression, LDH levels, metastatic dis-
ease and treatment response was similar in all three groups. 
Adverse events were not recorded in the Nordic NEC reg-
istry, and hence, analysis of the safety profile could not be 
performed. Patient and disease characteristics are presented 
in Table 1.
Survival data
PFS and OS showed no differences between the three 
groups. Median PFS for the whole cohort was 4.6 months 
and OS 13 months (Fig. 1a, b). Median PFS for the IV 24 h 
was 3.8 months, 5.6 months for 5 h infusion and 5.4 months 
for oral treatment. OS was also similar between the three 
groups; 14.5 months for IV 24 h, 11 months for 5-h infusion 
and 11.3 for oral administration.
Association between administration and prognosis
Kaplan–Meier analysis for the three administrations did not 
show differences in PFS and OS (Fig. 1c, p = 0.67, Fig. 1d, 
p = 0.59). Additional analyses, comparing survival curves 
for 3 and 6 months, showed no differences in the short-term 
progression between the three groups (data not shown).
Table 1  Patient and baseline disease characteristics
Performance status: ECOG the Eastern Cooperative Oncology Group 
consensus for performance status, Response RECIST criteria, IV 
intravenous, LDH lactate dehydrogenase, O.E. oral etoposide
IV 24 h, n (%) IV ≤ 5 h, n (%) O.E., n (%)
170 33 33
Sex
Male 86 (51) 20 (61) 18 (55)
Female 84 (49) 13 (39) 15 (45)
Primary tumor
Esophagus 6 (3) 2 (6) 0 (0)
Stomach 10 (6) 2 (6) 4 (12)
Pancreas 48 (28) 8 (24) 10 (31)
Colon 35 (21) 7 (21) 4 (12)
Rectum 12 (7) 3 (9) 3 (9)
CUP 59 (35) 11 (34) 12 (36)
Chromogranin A immunoreactivity
Positive 142 (86) 24 (80) 26 (85)
Negative 23 (14) 6 (20) 4 (15)
Synaptophysin immunoreactivity
Positive 153 (94) 33 (100) 29 (94)
Negative 9 (6) 0 (0) 2 (6)
Performance status
0 59 (37) 11 (34) 8 (25)
1 83 (52) 16 (48) 17 (53)
2 14 (9) 5 (15) 6 (19)
3 3 (2) 1 (3) 1 (3)
LDH
Normal 55 (41) 11 (33) 18 (62)
Elevated 80 (59) 22 (67) 11 (38)
Metastatic stage
Local 7 (4) 3 (9) 1 (3)
Regional 41 (24) 4 (12) 6 (18)
Distant 122 (72) 26 (79) 26 (79)
Ki67
< 55% 79 (46) 19 (58) 17 (52)
≥ 55% 91 (54) 14 (42) 16 (48)
Response
Complete 5 (3) 0 (0) 2 (7)
Partial 41 (26) 8 (29) 8 (27)
Stable disease 59 (37) 10 (35,5) 13 (43)
Progressed disease 54 (34) 10 (35.5) 7 (23)
 Medical Oncology (2018) 35:47
1 3
47 Page 4 of 7
To assess the effect of administration on survival, cox 
regression models for univariate and multivariate analyses 
were used. We found no differences in progression and OS 
on the basis of administration when comparing oral admin-
istration to short and long infusion (Table 2, p = 0.54 and 
p = 0.91 for PFS and p = 0.38 and p = 0.90 for OS). A worse 
performance status and elevated LDH were significantly 
associated with poorer survival. Patients with performance 
status 2 + 3 showed an almost doubled risk of progression 
(p = 0.01) compared with patients with performance status 
0 and 1 and almost four times poorer survival (p < 0.01). 
Elevated LDH levels also associated significantly to shorter 
time to progression and poorer survival in this patient 
cohort. Patients with elevated LDH level had a 50% higher 
risk of progression and 70% risk of dying (p = 0.01 and 
p < 0.01, respectively). Data are summarized in Table 2.
In the multivariate model adjusted for sex, Ki67, CgA, 
performance status, LDH and metastatic stage, no statistical 
associations between administration route and progression/
survival were found (Table 3).
Discussion
In this large Nordic NEC register-based study, we examined 
differences in disease progression and survival for patients 
receiving etoposide as 24 h infusions, shorter infusions 
or O.E. The main finding is that there was no statistically 
significant differences between the three administration 
groups, which suggest that no one of these administration 
routes is superior to another.
The cox regression analyses showed that none of the 
administration groups in particular were associated to better 
or poorer PFS or OS. Additional analyses to further exclude 
the risk of confounding factors showed no significant differ-
ences between the three groups.
The data from this study suggest that, although more fre-
quently used, IV formulations may not be the ultimate route 
of administration.
Studies of head-to-head comparisons between IV etopo-
side and O.E. are limited with conflicting data. Some studies 
suggest that O.E. is better or at least equally effective as IV 
etoposide and some studies report the opposite. O.E. given 
to patients with ovarian cancer and prostate cancer as the 
second-line treatment showed the same or better efficacy and 
safety as IV administration [18, 19]. In a study on patients 
with castration-resistant prostate cancer, the efficacy, com-
pliance and safety profile did not differ between etoposide 
given IV versus orally [19]. These results suggest, in accord-
ance with our results, that O.E. may be a valuable option to 
consider when treating patients with etoposide.
A study on patients with non-small cell lung cancer 
demonstrated that the safety profile for O.E. is significantly 
better to that of IV etoposide. In this cohort, there was a 
Fig. 1  Kaplan–Meier curves for PFS and OS. a PFS for whole cohort; b OS for whole cohort; c, d PFS and OS for the three administrations, 
intravenous long infusion (IV 24 h), intravenous short infusion (IV < 5 h) and oral etoposide (O.E.)
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significantly higher need for hospitalization due to neutro-
penia in the IV group compared to the oral group [20].
However, results favoring IV formulations have also been 
demonstrated. There are limitations of oral chemotherapy 
that may be the cause of their slow implementation in the 
clinic, such as variability in concentrations, uptake and 
safety profile. A study showed that O.E. has three times 
higher intra-patient variability and twice as high inter-patient 
variability when compared to IV formulation of the drug 
[17]. How important these inter- and intra-patient variabili-
ties are for the survival of the patients is not concluded. 
Drug–drug interaction is another concern when giving 
etoposide orally. Etoposide interacts with the commonly 
used antifungal agent, ketoconazole, resulting in an increase 
in the etoposide concentration systemically [21].
The oral administration route for etoposide is an easier, by 
patients often preferred approach rather than IV infusions. 
An 89% preference for oral chemotherapy compared to IV 
was reported in a study from 1997 and in a meta-analysis 
of 13 research papers in 2016, the reported preference for 
oral chemotherapy was 85%. These results indicate a strong 
patient preference for oral administration, with no clear 
studies refuting the use of oral chemotherapy [22, 23]. Oral 
chemotherapy also decreases the cost associated with hospi-
tal stays for infusions, and it decreases the pains of puncture 
wounds in patients and offers a more convenient alterna-
tive. The cost effectiveness of oral chemotherapy has been 
investigated in few studies and many times with favorable 
outcome for the oral formulations [24, 25].
In conclusion, there are no conclusive results to indicate 
which route of administration of etoposide is superior. Our 
results indicate that the three ways of administrating etopo-
side did not differ with regard to efficacy in PFS or OS and 
that oral may be favorable option for cancer patients in a 
palliative setting.
Table 2  Univariate analysis
Hazard ratio (HR) and 95% confidence intervals (CI) obtained from 
cox regression models
CgA chromogranin A, ECOG the Eastern Cooperative Oncology 
Group consensus for performance status, IV intravenous, LDH lactate 
dehydrogenase, O.E. oral etoposide
*Correlation is significant at the 0.05 level
**Correlation is significant at the 0.01 level
Progression-free 
survival
Overall survival
HR (95% CI) p value HR (95% CI) p value
Administration
IV ≤ 5 h versus 
O.E.
1.2 (0.7–1.8) 0.54 0.8 (0.6–1.2) 0.38
IV 24 h versus 
O.E.
1.0 (0.5–1.7) 0.91 1.0 (0.6–1.6) 0.90
Sex
Male versus 
female
1.0 (0.7–1.3) 0.92 0.9 (0.7–1.2) 0.65
Ki67
< 55 versus ≥ 55% 1.0 (0.7–1.3) 0.92 1.3 (0.9–1.7) 0.12
CgA immunoreactivity
Positive versus 
negative
1.0 (0.7–1.5) 0.92 1.3 (0.9–1.9) 0.23
ECOG performance status
0 + 1 versus 2 + 3 1.8 (1.2–2.8) 0.01** 3.8 (2.5–5.7) <0.01**
LDH
Normal versus 
elevated
1.5 (1.1–2.1) 0.01** 1.7 (1.3–2.4) <0.01**
Metastatic stage
Local versus 
distant
1.0 (0.4–2.6) 0.96 0.9 (0.5–1.8) 0.76
Regional versus 
distant
0.9 (0.4–2.4) 0.95 1.0 (0.5–2.0) 0.91
Table 3  Multivariate analysis
Hazard ratio (HR) and 95% confidence intervals (CI) obtained from 
cox regression models
CgA chromogranin A, ECOG the Eastern Cooperative Oncology 
Group consensus for performance status, IV intravenous, LDH lactate 
dehydrogenase, O.E. oral etoposide
*Correlation is significant at the 0.05 level
**Correlation is significant at the 0.01 level
Progression-free 
survival
Overall survival
HR (95% CI) p value HR (95% CI) p value
Administration
IV ≤ 5 h versus 
O.E.
1.2 (0.7–2.2) 0.42 1.1 (0.6–1.8) 0.79
IV 24 h versus 
O.E.
1.0 (0.5–1.9) 0.99 1.1 (0.6–1.9) 0.86
Sex
Male versus 
female
0.9 (0.7–1.3) 0.71 0.8 (0.6–1.1) 0.22
Ki67
< 55 versus 
≥ 55%
1.1 (0.8–1.6) 0.57 1.3 (0.9–1.8) 0.17
CgA immunoreactivity
Positive versus 
negative
0.7 (0.4–1.1) 0.13 0.8 (0.5–1.3) 0.35
ECOG performance status
0 + 1 versus 2 + 3 1.9 (1.2–3.3) <0.01** 3.8 (2.4–6.2) <0.01**
LDH
Normal versus 
elevated
1.4 (0.7–2.0) 0.07 1.6 (1.1–2.2) 0.02*
Metastatic stage
Local versus 
distant
1.1 (0.4–2.9) 0.88 1.2 (0.6–2.6) 0.62
Regional versus 
distant
0.9 (0.4–2.5) 0.91 1.2 (0.6–2.5) 0.59
 Medical Oncology (2018) 35:47
1 3
47 Page 6 of 7
Previously, studies have shown conflicting results lead-
ing to a disadvantage for oral chemotherapy being used 
clinically. However, our data imply that oral administration 
of etoposide may be a good alternative for GEP-NEN G3 
patients. Prospective studies are needed in order to validate 
and establish a consensus on the efficacy of oral chemo-
therapy and whether this option is being overlooked with 
regard to cost effectiveness, safety and patient preference.
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